{"id":"NCT00116584","sponsor":"University of Louisville","briefTitle":"Heliox-Driven Racemic Epinephrine in Treatment of Bronchiolitis in Pediatric ED Patients","officialTitle":"The Use of Heliox Driven Racemic Epinephrine Nebulization in the Treatment of Moderate to Severe Bronchiolitis in Pediatric Emergency Department Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-12","primaryCompletion":"2008-03","completion":"2011-10","firstPosted":"2005-06-30","resultsPosted":"2020-05-20","lastUpdate":"2020-05-20"},"enrollment":72,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Bronchiolitis"],"interventions":[{"type":"DRUG","name":"heliox","otherNames":[]},{"type":"DRUG","name":"oxygen","otherNames":[]}],"arms":[{"label":"heliox","type":"OTHER"},{"label":"oxygen","type":"OTHER"}],"summary":"The purpose of this study is to assess whether children with moderate to severe bronchiolitis treated with standard racemic epinephrine therapy via 70:30 helium-oxygen (heliox) driven nebulization will have improvements in measurements of airway more rapidly than those treated with conventional air-oxygen driven nebulization.","primaryOutcome":{"measure":"Change in Modified Wood's Clinical Asthma Score (M-WCAS) From Baseline to 240 Minutes","timeFrame":"240 Minutes","effectByArm":[{"arm":"Heliox","deltaMin":1.84,"sd":null},{"arm":"Oxygen","deltaMin":0.031,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.05"}]},"eligibility":{"minAge":"2 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":17},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["22147778"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":34},"commonTop":[]}}